AOD-9604 vs Amlexanox
A side-by-side research comparison of AOD-9604 and Amlexanox across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Amlexanox |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Amlexanox (TBK1/IKKε Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Research / Off-label |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. |
| Molecular weight | 1815.08 Da | 298.29 Da |
| Half-life | ~2-3 hours | ~3-4 hours |
| Bioavailability | ~90% subcutaneous | ~70% oral |
| Typical dose | 300 mcg | 25-100 mg |
| Frequency | Daily (morning, fasted) | 3x daily |
| Route | Subcutaneous injection | Oral tablet |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Related comparisons
Research and educational reference only. Not medical advice.